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In this study, 796 men with unstable coronary artery disease (that
is, unstable angina or non-Q wave myocardial infarction) were
randomized to double-blind placebo-controlled treatment with
aspirin (75 mg/day). The long-term efficacy was judged from the
occurrence of myocardial infarction or death or severe angina
necessitating referral to coronary angiography .
The risk of myocardial Infarction or death was reduced during
aspirin treatnent-after 1 year, the risk ratio was 0.52 (confi-
dence interval 0.37 to 0.72). Severe angina necessitating referral
to coronary angiography was less common during aspirin their
.
apy-after 3 months, the risk ratio was 0 .59 (0.42 to 0.84) and
Progression of coronary artery disease is caused either by
growth of atherosclerotic plaque or by accumulation of
thrombotic material at a coronary lesion . The clinical con-
sequences of progression of a coronary lesion depend on the
degree of reduction of coronary blood flow, the development
of collateral vessels and the myocardial oxygen demand .
Unstable coronary artery disease (that is . unstable angina or
non-Q wave myocardial infarction) is often caused by a
fissure in plaque and an accumulation of platelets . fibrin and
red blood cells suddenly decreasing the coronary artery
lumen and reducing myocardial blood supply (I-10). The
further development of a new lesion might be influenced by
treatment with platelet inhibitors
. This treatment might
affect not only the risk of thrombotic occlusion and myocar-
dial infarction, but also the coronary blood flow reduction
and thereby the symptoms of angina and the need for
coronary angiography and revascularization .
Previous studies (11-17) have established the protective
effects of 165 to 1,500 mg of aspirin and other platelet-
inhibitory drugs after myocardial infarction and unstable
angina. We recently demonstrated (I8) a comparable protec-
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after I year 0.71 10 .56 to 0.91) . The combined event rate of
myocardial infarction or death or referral to coronary sngiogra-
phy was reduced ; after 3 months, the risk ratio was 0.74 (0.30 to
0.66) and after I year 0
.65 (0 .54 to 0
.79)
. The 75-mg aspirin dose
was well tolerated and had a high level of patient compliance .
Treatment with aspirin (75 mg(day) should be recommended to
all men for ?3 months after an episode of unstable coronary
ac -- disease . Long-term therapy should be considered if there
are no contraindications or side effects
.
(I A. Call Cardiel 1991 ;18 :1587-93)
tive effect of 75 mg)day of aspirin during the first 3 months
after an episode of instability in coronary artery disease . To
date, there are no studies that demonstrate any effects of
aspirin on other consequences of coronary artery lesions .
Therefore, we evaluated not only the protective effect of
75 mg of aspirin with respect to myocardial infarction . but
also its influence an symptoms of angina and the need for
coronary angiography and revascularization during long-
term follow-up.
Methods
The design was a prospective randomized double-blind
placebo-controlled multicenter study in men <70 years of
age. The primary aims were to evaluate whether 75 mg/day
of aspirin had any effect on the incidence or time of occur-
rence of myocardial infarction or severe angina necessitating
revascularization after an episode of unstable coronary
artery disease
. The design of the study and the short-term
outcome regarding risk for myocardial infarction have pre-
viously been reported (18) .
Inclusion and exclusion criteria . Unstable coronary artery
disease was defined as either a non-Q wave myocardial
infarction or increasing symptoms of anginal chest pain at
effort or rest starting within the preceding 4 weeks and
associated with signs of ischemia either on the electrocar-
diogram (ECG) at rest or during a predischarge exercise test .
All men <70 years of age admitted to the coronary care unit
because of symptoms that warranted the suspicion of unsta-
0735.109791153 .50
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ble coronary artery disease and without any reason for
exclusion were randomized to start treatment no later than
72 h after admission . Reasons for exclusion were acute
myocardial infarction with development of Q waves or peak
creatine kinase > 15 µkat/liter
; QS complexes in at least two
adjacent chest leads ; myocardial dysfunction treated with a
combination of diuretic drugs and digitalis or vasodilators ;
valvular heart disease ; previous coronary bypass surgery ;
left bundle branch block, pacemaker rhythm or heart rate
> 150 beats/min ; inability to perform an exercise test because
of a physical handicap ; noncardiac disease with a poor
prognosis ; long-term treatment with anticoagulant agents or
aspirin ; increased risk of bleeding; allergy to aspirin ; pre-
sumed problems of compliance ; or participation in a trial or
refusal to participate . According to the study protocol,
patients with neither enzyme leakage nor signs of ischemia
on any ECG at rest were definitely included only if a
predischarge exercise test showed signs or symptoms of
ischemia.
Treatment and follow-up . The randomized treatment
started within 72 h after admission to the coronary care unit
(that is, as soon as an elevation of cardiac enzymes was
disproved or !he maximal enzyme level was passed)
. One
tablet a day of either aspirin (75 mg) or placebo was given
from the day of randomization . The randomized treatment
was planned to continue for ml year, but was prematurely
terminated if the patient had Q wave myocardial infarction,
a coronary revascularization procedure, intolerable side
effects or another disease that prohibited maintaining ran-
domized aspirin treatment .
No drugs containing aspirin, other nonsalicyclale anti-
inflamatory preparations or anticoagulant agents were al-
lowed during the study . Treatment compliance was moni-
tored by tablet count in all and by monitoring platelet
aggregation in a subgroup of participants .
Immediately after admission, all patients without con-
traindications were treated with a beta-adrenergic blocking
agent, usually oral metoproloi (100 to 200 mg/day). Patients
with ongoing or recurring chest pain were also treated with
nitrates or a calcium channel antagonist, or both . Standard-
ized forms were used to record cardiac symptoms and side
effects of medication at the outpatient visits after I, 3 and 12
months .
Laboratory methods. Serum levels of creatine kinase
were obtained (at seven of eight hospitals) on admission and
every 6 h for 18 h or until the peak level was reached .
Aspartate aminotransferase levels were measured in all
hospitals at admission and every 24 h for 2 days . Blood
hemoglobin concentration was measured before the start of
treatment and during outpatient visits
. Tests of platelet
aggregation ex vivo in an aggregometer (19) were performed
in a subgroup of patients at the coordinating center before
and after I and 12 months of treatment .
A 12-lead ECG at rest was obtained on admission and
once daily during the next 2 days ; it was also recorded at
every outpatient visit . A symptom-limited exercise test using
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bicycle ergometry was performed before discharge in all
patients who became free of chest pain at rest during
treatment in the hospital, as reported previously (18,20,21) .
The exercise test criteria for definite inclusion of patients
with neither ST-T wave changes on the ECG at rest nor
elevation of cardiac enzymes were the following
: occurrence
of ST segment depression 00
.1 mV or limiting chest pain or
a maximal work load <100 W without any obvious extrac-
ardiac reason .
End points
. According to the study protocol, the random-
ized treatment was planned to continue for ?I year. How-
ever, after publication of the Second International Study of
Intravenous Streptokinase (ISIS-2) results in August 1988
(16), demonstrating the efficacy of 165 mg of aspirin in acute
myocardial infarction, an ad hoc safety committee (Appen-
dix) was formed that on ethical grounds recommended
premature termination of the study . The randomized treat-
ment was stopped in all patients and the study terminated in
the beginning of October 1988 . Thus, the minimal time of
treatment and follow-up was reduced to 3 manthd .
Definitions . Severe angina in the hospital was defined as
repeated episodes of chest pain at rest or on slight effort,
despite maximal antianginal medication, requiring urgent
coronary angiography and revascularization . During later
follow-up, severe angina was considered present in patients
with incapacitating episodes of chest pain (Canadian Cardio-
vascular Society class III or IV) during treatment with a
combination of antianginal drugs also leading to referral for
coronary angiography and revascularization . The findings on
the ECG at rest or the predischarge exercise test had no
influence on the decision for referral to coronary angiogra-
phy in this study.
Myocardial infarrtion was diagnosed in patients readmit-
ted to the hospital and fulfilling international diagnostic
criteria after examination of the medical records, ECG and
laboratory results (18,22) . All end points were scrutinized by
the Steering Committee without knowledge of the treatment
given
. Permission to perform the study was obtained from
the Ethical Committee of the Linkoping University Hospital
and the Swedish Social and Welfare Board .
Statistics . According to the study protocol, the analyses
were to be based on the occurrence and time of death or
myocardial infarction or severe angina in patients subse-
quently confirmed to have met all criteria for definite inclu-
sion in the study and who had received at least one oral dose
of the study medication
. Events after coronary revascular-
ization or Q wave infarction were not included because these
were predetermined end points of the study . Follow-up was
complete in all patients for 12 months or until the termination
of the study .
The analyses were performed according to the "intention
to treat" principle . Comparisons between treatment groups
during different time intervals were performed by log-rank
chi square tests with continuity correction . Estimates of risk
ratios were calculated using the Cox proportional hazard
model.
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Table 1. Comparison of Baseline Characteristics BI- the
Groups Treated With Aspirin 175 mgiday) and Placebo
"p = 0 .02 ; It, _ 0.03 . all other differences am nonsi&nincart Ip 5 0 .11 .
Ca- calcium channel; ECG = elecomendiogzm; HDL
:hot = high density
lipoprotein cholesterol .
Results
Study patients (Table 1) . Between May 1985 and June
1%8, 8,136 men <70 years of age were admitted to the
coronary care units of the participating hospitals . According
to their history 3,365 men fulfilled the inclusion criteria .
Because of the predefined exclusion criteria, 2,420 men were
not eligible (18)
.
After informed consent, 945 patients were
randomized and started the study medication : I 15 men who
primarily were it-luded because of chest pain but without
signsof ischemia on the ECG at rest and without elevation of
cardiac enzyme levels were excluded after an coercing test
without any signs or symptoms of myocardial ischemia. Of
these 115 men, 58 had been randomized to placebo and 57 to
aspirin therapy . During [-year follow-up, 2 of the 58 random-
ized to placebo underwent revascularization and 2 of the 57
randomized to aspirin had a non-Q wave myocardial infarc-
tion .
Thirty-four men were excluded after the examination at
the central ECG laboratory because their ECG at rest
showed a predefined exclusion criterion lanteri,r Q Love
myocardial infarction before inclusion). Of these 34 men, 16
had been randomized to placebo and 18 to aspirin therapy .
During follow-up for I year, 3 of these 34 patients had a
w ALLEN IIN t r AL .
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Table 2
. 5
; yrxardia1 Infarction' During Treatment With Aspirin
175 or ,d:M .,r 11--h. ae
the'fermmanon of the Study or After a
hintitronts of I'- Slonthv of Follow-tip
.Q
Is','
',Q)
or In Q ware myecardtal infarction 11111 nr death .
-In, JO--d
hr ch,
.,quare anal,rts p = NS wnh 95, confidence
'mlcnal 'Ctl l,cludiru, .,lues >, .
mvocanlial infarction 12 randomized to placebo and I to
aspinn) and 2 underwent revascularizauon II from each
grnupl . Therefore . 796 patients remained for definite inclu-
sion
. Thu
., 9V
, of admitted men <70 years of age and 2491
of those who tulnllcd the inclusion criteria were finally
included : of these, 399 patients were randomized to aspinn
and 397 to placebo .
Boselinc churnrreristics it, the groups receiving aspirin
and placebo arc compared in Table 1 . There were only minor
differences between the two groups .
3lyetardial infarction (Table 2)
. After 6 and 12 months of
aspirin treatment . the risk of myocardial infarction or death
was reduced by 547c and 4879, respectively (two deaths in
each group wore of noncardiac origin). Thus, the gains
obtained during the lsl 3 months, after which the risk was
decreased by 649, were retained over a longer time period
lFig. 1) .
Sevare angina ITables 3 and 4) . A difference in referral to
coronary angiography emerged during the 1st 3 months, after
Figurel. Risk ,.fmyocardial infnrctinnor death during 12 months o
fallow-op according m allocation to 75 un/day of aspirin (ASA) or
Pin- (Place
. The ereph
is a life-table depiction of the -mutative
risk and time for !he occurrence eras outcome event . the numbers
of portenis al rak in each group are noted below the gmph.
Clinic,! Findings
Placebo
(a = 3971
Aspirin
(a = 3991
Reason for inclusion
Non-Q wa a Intamlion 12) 49.1 48 .4
Rest angina (9t) 23 .7 21_6
Increasing angina 191
18.4 318
Recent onset
angina
9.) 9?
ECG at admission
ST eleraGOn
1701 20.4 2C:
ST depression (9) 392
35 .1
T wave inversion 191 76.1 'i.0
History
Pneaiom ablation 751 231 l&3
Angina at rest last month (n) 41 .0 36,3
Increasing angina <R days (71) 36 .1 36,9
Increasing angina 8 to 30 days Inn 24 .1 24 .1
Bera'blcokade at admission 17791 33 .3 330
Ca inhibitor at admhsion 1%) 14 .6 12 .8
Nitroglycerin prophylazis
1951
11
.0
13,3
Other .kg-ad factors
Mca; ngc (yr) g.0
58
,5
Smoker 191 36.7 19.1
Hvacrteminn l%I 29.9 11 .2
Mean ehnleOrrol lmmolllilen 6.03 s,9n
Mean Iriglycerides (mm001iter) 2cm
I .b(
Mina HIM chot(mmollitert 0.61 710
D,'a0eten mellitus 191
7.. 8 .3
Mean body weight (kg)
82.0 80 .2'
Occasional aspirin last week (9) 16.9 18,6
Pl'1-eb.
(r
- 3971
.Aspirin
In = 199)
Risk Ratio
ICI)
P
Value'
,111-Jralh 0.4610 31-0.67) <( .0001
Q 111-Jsdh '4 0.10103'-0.771 0.1102
Peach 1,
05310'-3-1 .29, NS
0,111,
61I`de11h 44 0 .52 (0 37-0.72) 0.0011
1351)-death NI 34 0.561o3R-0 .041 1.0110
Death IS iI 0.6110'9-1_'71 NS
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Table l. Severe Angina (referral to coronary angiography)
During Treatment With Aspirin (75 mg/day) and Placebo
at the Termination of the Study or After a Maximum of
12 Months of Follow-Up
Time Placebo Menu Risk Ratio p
10 17 0 .5610 .32-1 .01) 0.068'
3 72 43 0.59 (0.42-0.84) 0.004
6 93 68 0.7310.55-0.961 0.031
12 116 83 0.71 (0.56-0 .91) 0.008
'p values determined by chi.square a nalysis
. tp = NS with 95% confi-
dence interval ICI( including values TI .
which there was a 44% reduction in the number of patients
with pharmacologic failure in the aspirin group (Table 3) .
Thereafter, the number of referrals was comparable in both
groups . However, the gains obtained during the Ist 3 months
brought about a remaining reduced need for revasculariza-
tion for ?l year (Fig . 2).
A subgroup analysis (Table 4) demonstrated that aspirin
seemed to reduce the occurrence of severe angina regardless
of inclusion criterion (non-Q wave infarction or unstable
angina) and in all groups with any sign of ischemia on the
ECG at rest or during exercise . Aspirin treatment was
ineffective with respect to the need for revascutarzation in
the small number of patients who were being treated with
oral nitroglycerin or a calcium channel antagonist before
entry into the study and who probably represent those with
the most severe disease before inclusion
.
Revascularization. Many revascularization procedures
were performed on an elective basis, which at the time
Table 4 . Subgroup Analysis Based on Findings at Entry Regarding Occurrence of Severe Angina
After 12 Months of Treatment With Aspirin (75 mg/day) in Comparison With Placebo at the
Termination of the Study or After a Maximum of 12 Months of Follow-Up
'p values determined by chi-square analysis with 95% confidence interval ICI) including values >1. Ca= calcium
channel : EGG = electrocardiogram.
JACC Val . 18, No. 7
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Figure 2. Severe angina and need for coronary angiography during
12 months of follow-up according to allocation to 75
mg/day
of
aspirin (ASA) or placebo (Plac) . Format as in Figure l .
Imo)
In = 397) In = 399)
(Cl)
V l e-1
implied awaiting time of 6 to 8 months between the time of
referral to angiography and the intervention . Because of the
delay of revascularization, several interventions occurred
after the conclusion of the study and were therefore not
included in the present analysis . It could still be demon-
strated that aspirin treatment reduced the number of revas-
cularization procedures. The number of such procedures
performed in the placebo and aspirin groups, respectively,
was I I
and 3 (p = 0 .06) after 1 month, 21 and 10 (p = 0 .07)
after 3 months and 65 and 43 (p = 0.03) after 12 months .
Combined events (Table 5). When the first event (death,
myocardial infarction or severe angina) was taken into
account, there was a considerable reduction in the event rate
Subgroup
(no
. placebolaspiris
Pmcebe
(n=397)
Aspirin
(n=399)
Risk Ratio
(CO
P
Value'
Inclusion criteria
Non-Q wave MI 119511931 51 33 0.65 (0.44-0.96) 0 .041
Unstable angina 1202(2110) 6.5 50 0.75 (0 .53-1 .031 NS
Rest
ECG
ST segment change (19411511
59 42 0.75 (0 .53-1 .05) NS
No ST segment change 12031216) 57 41
0.68 (0.48-0.96) 0 .037
T wave inversion (300307) 89 62 0 .68 (0.51-0.91) 0 .010
No T wave inversion (95192) 27 21
0 .50 (0.49-1 .31) NS
Exercise ECG
ST depression1192(192) 75 50 0 .70(0.52-0.94) 0 .02
Na ST depression (1661190) 28 27 0.84(0 .52-1 .37) NS
Drags at entry in hospital
Bets-blocker 113311201 51 31
0 67 (0.46-0.981 0.046
No beta-blockade (2641279) 65 52 0.76 (0.55-1 .05)
NS
Ca inhibitor 155(511
26 23 1 .00 (0 .66-1 .531 NS
No Ca inhibitor 039648) 90 60 0.65 (0 .49-0.57)
0.004
Oral nitroglycerin (47153) 19 23 1 .0710 .68-1 .711 NS
No peal nitroglycerin (350(346) 97 60 0.6310.47-0.831 0.001
4ACC W.18. No.7
December 1991:1,
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Table 5 . Combined Events' During Treatment With Aspirin
(75 mgldayl or Placebo al the Terminal- of he
Study or After a
Maximum of I'- Months of Follow-Up
Time
	
Placebo Aspirin Risk Rut
p
Into) In = 197) In = 7991 I('it Value
I 70 )1 .44111!11-n.vvt
<0Aanl
c, o5uur7N-0.151 <n .aml
6 148 N9
It61111148 i1 t1 0_1r111
12 171 112 11 651n r4-11741
<11 e i 1
'Firs! event of Jeath . any-dial infarction o rcquu
referral to coronary angiography . tp
values Jeteraline I h) chi square anal) o,
mob 9Y, oontdrree interval ICII rclmtion 'aloes 'I
from the 1st week in the hospital and during the 12 months of
follow-up (Fig. 3). Also, with respect to the combined
events, the major benefits of treatment were observed during
the let 3 months after the episode of instability .
Compliance
. In patients who had the 12-month outpatient
visit. 89% remained on the randomized treatment (p = NS
between the aspirin and placebo groups) . According to tablet
counts, 979 of placebo-and 9791 of aspirin-treated patient-
who continued the scheduled treatment had consumed ?75
tablets at the 3-month visit and 939 to 94Sn had consumed
>330 tablets at the 12-month visit (p = NS between groups) .
The compliance to and efficacy of aspirin treatment were
controlled by determination of platelet aggregation in a
subgroup . In the patients treated with 75
mg/day of aspirin .
the maximal aggregation induced by collagen I I mglluerl teas
reduced from 77 .7 ± 17.7% (n =
521
before to 35 x 14 .6
(n = 100) and to 42 .1 a 17 .9 (n = 841 after 1 and 12 months
of treatment . respectively . In the placebo-treated patients,
the collagen-induced aggregation was unchanged-81 .2
.
10 .7"/ (n = 52) before the study compared with 81 .9
.
0°)
(n = 96) and 81 .8 * 11 .19 1n = 71) after I and 12 months.
respectively, while receiving placebo.
Figure 3. Risk of myocardial infarction or death or severe angina
necessitating coronary angiography during I'- months of follo-up
according 'a allocation to 75 mgday of aspuin ( .ASA) or placebo
(Pled . Formal as in Figure I .
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Side effects . Side effects of bleeding were rare and minor ;
occasional episodes of bleeding during toothbrushing or
shaving . cpislasis . hematuria or hemorrhoidal bleeding were
reported in a few patients (0 .7%) on aspirin treatment at the
12_-month visit
. There was only one major complication
during long-term treatment lone case of cerebral needing in
as aspirin-treated patient after I year)
. Mean hemoglobin
concentration determined in all patients at every visit was
unchanged and there were no differences between the aspirin
and placebo groups . Gastrointestinal side effects were some-
what inure frequent in the aspirin (3 .854) than in the placebo
(2.8°)) group after 12 months
. Few patients stopped the
randomized trealocal during follow-up because of presumed
aspirin-related side effects (3
.19 in the aspirin-treated com-
pared with 0 .9 •' ' in the placebo-treated group) . Symptoms
that could he considered as side effects of amianginal drugs
were reported by 16,5 ff and this were considerably mere
common than the side effects of 75 mg of aspirin .
Discussion
Design . The present study concerned only men because a
previous pilot study demonstrated that women admitted to a
coronary care unit with similar symptoms and alterations on
the ECG at rest and during exercise had a very low event
tale during the following year . Furthermore. 509 of women
with chest pain that required coronary angiography had no
significant lesion despite signs of ischemia on the ECG at
rest or during exercise 121).
A decreased occurrence of severe angina and a reduced
need for revascuiarization during treatment with aspirin or
other platelet inhibitors have not previously been demon-
'tr,;ted . Therefore . it is important 'a elucidate any possible
bias that might have influenced the results . There were no
statistically significant differences in baseline characteristics
betaveen the treatment groups . Still, the aspirin-treated
group had somewhat fewer patients with angina at rest,
fewer receiving beta-blocker or calcium antagonist therapy
and fewer with S T depression on the ECG at entry (Table 2) .
However. even after patients were stratified into subgroups
based on different indicators of ischemia at entry, aspirin
treatment was shown to reduce the occurrence of severe
angina in the majority of patients (Table 41 . Therefore . it
seems unlikely that any possible differences between the
groups at baseline could explain the differences in the
incidence of severe angina . At some occasion . the occur-
rence of a non-Q wave infarction during fellow-up, which
was more common in the placebo than in the aspirin group,
might have boon considered an expression of refractory
ischemia and led to referral for revascuiarization . However,
also after a tclusien of patients with
--infarction,
there was a
reduced need for revascularizatic n in the aspirin group (data
not shown) .
The occurrence of severe angina and the indication for
coronary angiography were based on subjective opinions
that might have varied among the individual investigators in
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the eight hospitals
. The present study was performed at a
time when the resources for coronary angiography and
revascularization were very limited in Sweden
. In this
period, the only accepted indication for coronary angiogra-
phy was incapacitating symptoms despite medication with at
least two of the three conventional antianginal regimens (that
is, organic nitrates, beta-blockers and calcium channel an-
tagonists) . In the present multicenter study, the participating
hospitals had only one referral center for coronary angiog-
raphy and revascularization- the coordinating center-and
no private alternatives . These conditions facilitated keeping
the indications for coronary angiography and revasculariza-
tion unchanged and similar in all participating hospitals .
Previous results, In the placebo-controlled study by
Lewis et al . (11) of aspirin (330 mg/day) in unstable angina,
there was a trend to performance of more revascularization
procedures in the placebo than in the aspirin group during
the 3-month follow-up. In contrast. Cairns et al . (12), who
compared (1,200 mg/day) with placebo in unstable angina,
found no difference in the revascularization rate during 2
years . In a study (17) of the platelet-inhibitory drug ticlopi-
dine in unstable angina, there was no effect on need for
revascularization during 6 months of follow-up . However, a
long-term study (23) of patients with stable angina recently
demonstrated that aspirin (990 mg/day) reduced the occur-
rence of new coronary lesions as shown by repeated coro-
nary angiography . A beneficial effect of aspirin on the
seventy of angina and the future need for revascularization
might be !sore prominent in patients with unstable disease
and recent coronary lesions with a thrombotic component
than in patients with stable coronary artery disease.
Mechanisms . The idea that platelet inhibitors might have
an effect not only on thrombotic occlusion of arteries but
also on the development of nonocclusive lesions has arisen
from the discoveries of the interactions between platelets
and the arterial wall by means of the platelet-derived growth
factor, the thromboxane-prostacyelin balance and results in
animal experiments (3) . Attempts to demonstrate any influ-
ence of platelet inhibitors on exercise-induced stable angina
have failed and there are a few results indicating effects on
angina at rest (24,25), The earlier results might have been
influenced by the use of very high aspirin doses compared
with the 75-mg/day dose used in the present study . This dose
seems to give full inhibition of collagen-induced platelet
aggregation and thromboxane-A, synthesis and the prosta-
cyclin generation seems to be at least partially spared
(26-30) .
Duration of treatment efficacy . The main protective effect
of aspirin (75 mg/day) with respect to both myocardial
infarction and severe angina occurred during the Ist 3
months in the present study . Thereafter, the rate of myocar-
dial infarction and of occurrence of severe angina was lower
and comparable between the two groups. Also, in other
long-term studies of platelet inhibition in unstable angina
(12,17), the main protective effect was observed during the
initial 3 months . This could be explained by a stabilization of
the coronary lesion with a reduced risk of coronary throm-
bosis and occlusion after a few months. However, the
randomized groups will not be comparable after 3 months .
Al that time, many high risk patients will be eliminated from
the placebo group because of coronary events and more
patients will remain in the actively treated group. Perhaps
the high risk patients still are protected by the continuing
platelet inhibition .
Need for revascularization . A fairly large proportion of
patients in both groups had a cardiac event defined as either
death, myocardial infarction or severe angina during the
long-term follow-up
. After I year, 44% in the placebo group
compared with 29% in the aspirin group had any of these
events . Thus, aspirin treatment decreased or retarded but in
no way eliminated the need for revascularization .
Side effects
. Aspirin-related side effects of long-term
treatment were rare . However, even with the 75-mg dose,
there were some indications of gastruintestinal side effects in
a few patients, corroborating previous observations (31).
There were no signs of an increased occurrence of manifest
or occult bleeding. Very few patients terminated the aspirin
treatment because of side effects .
Clinical implications. The reduction of combined
events-death, myocardial infarction and refractory an-
gina-daring I year of treatment with aspirin (75 mg/day)
was impressive and side effects were rare . Aspirin at this
dose is extremely inexpensive and the treatment will be very
cost-effective. Therefore, treatment with low dose aspirin
(75 mg/day) should start as soon as possible and continue for
a3 months after an episode of unstable coronary artery
disease provided there are no absolute contraindications .
Continuous treatment for a longer period should be consid-
ered in all men after an episode of unstable angina or non-Q
wave myocardial infarction if there are no side effects during
the initial 3 months.
During the last few years, the resources for coronary
angiography and revascularization improved considerably in
Sweden . Today, it is our view that coronary angiography
should be performed not only in patients with incapacitating
symptoms, but also in those with signs of ischemia on
exercise testing or ST segment monitoring, or both . The
reasons for this policy will be further elaborated in forth-
coming reports .
Appendix
Sandy Panletpaaa and support'
f
hainnna and raardinarar
Lars Walleatin . MD. Professor. University Hospital. Linkoping.
Corneal Centers and romdpni fnsesexnrorr
University Hospital, Llnkliping: Ulf aerglund. MD, Ingvar Nun,, MD.
Huns Lawson MD,
Es, Swahn . MD, PhD .
Central Haspttat, Jonkaping : olof S--' MD.
Central Hpspital, Katnnr : Finn Landgrnn, MD
.
'All allies are in Sweden unless otherwise indicated .
tACC Vsl. 19. Nn. 7
Derember 1991 :1587-9r
'ACC Vol . IX. N .. 1
Llccmbcr 1991 :197-93
Central Horpilal . Norrkbping : Jun FriJen, MD . P-014 A,de,,,,, MD
Dislrid Hospital. Ekajo : Jan-Old Magnosson . MD . PhD .
DiSdet Haopilcl. Mmaln: Bengl-Olof Ryden. MD.
District Hoopibi. thkntshnmn: Bo Hedbaek . MD. PhD. Jeep Perk MD .
PhD.
DietrirtHospiml,V;aerrik : BJorn SinneroaJ,sa),
Drpurlmenrs If Clirri<'nl Plryniiloey
UnivereIIY Hospital, Linkoping : Nll,.Hulgtr Arcskog. MD. Probe-),
Central Hmpilal, Jonkoping: Mop- Alclkl_ MD. PI D.
Resrurch LRJmroion
UnivenRy Hospital. Linkoping. Ylva Svensson, Gnome] Almroth .
R,- -h Nnz
UNrenlly Hnpiht. Linkoping, Cairn Eellenlo. Ktntin Goms	
Srmi
.rcinns
Lmkuph% Univenily, Link .i ing: Erik L-J- PhD, John Crewmen .
PhD.
Plrorrrrnrrrr
Univenity Hospital, Linkoping . Sane Lindgren . PhD
Ad Ho, Spfen Cnnmriurr
London, England: Desmond Julian, MD .
Cdhbag: Las Wiihelmser
. MD, Haas W'edel . PhU.
Rddddmimd .tfedl	
Slwkholm. Kabi Phmma All
Helsingborg: Leo All .
Eton is 5gppnrr
Stockholm : Swedish Narionml
.Arrociarion again . horn-and Char; DI •-
eas Cmkepivg. Health Anthonly of Ostergdilavd Counrx .
GlIrbong : Haute All
References
I . Epaleie ES, Palmed T. Mechanisms conlnbuling to preclpiioion ni
unstable angina and are myocardial infarction implication rteardine
therapy. Am J Canfiul 1984:54:1245-32.
2 . Willenun IT. Campbell WB
. \9inniford MD .
I
A, Coma,iar. from
chronic to acute caranary artery hleole! peculation ravnrding meth,
msms . Am J Cordial 1984 ;54:1349-55,
3, Foster V . Steele PM. Chesebro JH . Role of al-1,1, and h,omto-,n
coronary atheroscltrolic disease and sudden death . I Am Coil Cardiol
1985_1:17513-84B.
4. Davies ML Thomas AC
. Plaque fissering-the rune oLsute myocardial
infarction
. sudden ischaemic death, and crnccndr
amino.
Br Hemt 1
1985:53
:363-73'5. Falk E . 11 able angina with Punt uulcomc : dynamic ooro,urry thromhn-
is leading to intntli.o cordon sudden death . Circulation 190:71:631-
708.
6
. Moseri A, Chierchia S . Doom s0 . Palhophysiulopy ,fonrnmrry omimion
in acute infarction, Circulmion 1915.73133_b.
7. Feklman RL
. Coronary lhromhos ny spmm and crro, other
.sclerosis amt specol,tion on the linkbnrwcn unaableungler and
myocardial infactlon. Am J Cardiol 1967 :i9: ;1N 1N7-90
8 . Hackelt D. Davies 4 Chicrchi;r S . Messed :S . Imtrmiuent cona .mocclusion in
-,
mmy-did
infactiou . V Engl I Mal 1987 :117:11155-9.
9 . Fualer
. Hadiman L. Cohen M, Amhrme JA . Bad,,,, 11 . Ch...No J .
insights into the pathogen ,n of a .me hchenn, y idrome • . Ciaulwion
193X :77 :1111-711,
I0, Richardson D, Davie, Nil
.
It,,,.
VR .Ind-
andues, distribution .n fin,uring n(avoa,oy'nhnrowleraic plaque .
Cancel 19X9;1 941-3 .
WALLENTIN ET IL.
	
1993
ASPIRIN IN LNSTABLE CORONARY ARTERY DISEASE
11 Lexi, H0 . Daxk 1W. Archibald D G . et al . Protective effects of aspirin
an,
-cordial
Infcrclion and death in men with unstable
na . N Enel I Med 1981 :309196-403.
C. Cairn, JA . Grnt M, Singer J, et of Aspirin sulfirpyra ore or bah n,
umiahleangioa S Eigi101ed 19X5 :9131369-7s .
I1 Ari,plaldd, Tr''-alixboration . Secondary prt,'enrion of raunlar
di •ea•e by prolanceJ antiplatelet treatment. Br Med 1 198X3% 120-1 .
14 . Yuatf S Will,, J . Friedman L. 0-vi- of recalls of randomized
dunk- Trial, In heart disearr . 1. Trrtment f.11-inc myocardial infarc-
tion . 1:1\1:1 19NN:261O_Jgb-93.
11
. Yard S . Sviut, J
. Fred- L
. Overiem of resells of mrdomited
clinical Iria6ln horn disease . II . Unnatde angina. heart failure, primary
prevention xoh ++ruin and risk factor modification . JA SIA 1988:_60:
2.9
16. ISIS'_ CoIL.h,rmi,e Groupo kandomi,ed Iria . :
r
s treplaki-
..• and a,piriv. Bath or mnhcr among 17187 •aacs .f ...pcclcn acute
cordial infarction: ISIS-I. lancet 19882349-1 .
1' . B:de,;mo P . RiuGn P. Violi E oral. Amiplaldcl Ircalmrnt withtidopidin .
or ntblt (ngl11 a ,mnrnlied malticenler clinical Irhl . Circulationl•se , _
INhe Restuch Ciroup on Instability in Coronary Ave,-y' Disrese In
Sswthca,t Sacden . Risk for rocoanhial infarcnon and death during
rcatmsm xith ;omen 75 mgidav and inrra,enoaa hep;rnn either or
)either in men xivh nnscrble coronas ..- disease. Lance) 1990:336:
Y•7
-311
la. Bergl,rd C . .r 5.henck H . Svallrntin L . Effects of odnpidreo on
,1-1" m n mrn xirh staple angina pec,on.,. Thromb Hxem0a
1930.993119-fort
.
211 . Sxahn E . .>rc •A og \I . VV'allentin L. Early eaercior cures rfttr caronoon
n (nnmpmmd mutable coronary artery dizeast Eon It.. 1 1901 :0
?74-61n .
I . Sxahn 6 brr,kne II . Bcrglund C. S"'alfriJnan H, Wxllentln L Predio
• imprrmnce r-f dimual findings and a pn,,h,,hxrge exercise text in
,wrested umtaMe aomnary artery diseases Am J Cordial 1981
:1
14 .
, . ollum RF . Finnem SP . Prime. RI . Koltke TE Initmational diagnoslie
cntoma fn--, myucurdiul infarction and stroke Prog Cardiol 1081
:111X:
150-7
Ch-loo IH . W<h,tcr 511VL Smith BC. a al. Amiplmtla ihcmpy in
nv di,c :nc progression : redeced infarction and ntw boron Cur-
lion n.h,nl. Cbcul:dion 1989 .81Nsuppl 111 :11- W6.
`4. Btrchmd t . I:-,,k C . Wallcnlin L. Effects of the platelet inhifimrv
drug ucloprdine on exercise 0.derunce in ztuMe angina Peaonx . Eur Heart
j 198':8',71-ill
'S . For VII
. Jonathan A. Sehcyn AP. Elf- of platelet inhibition on
-,
,,,dial R,Kt- . Lanret 1981:2 :772-30.
W'ek,ler B . Pen SD . Richter RC. et al. DIRe¢mial inhibition by ospmn of
	r:uivr and piarela peoslaplandin svaihesi, in alherosclerollc Parents .
N Fret I Mad 19911118 :300-1.
_7 . H,Gcralr G.S . Oau., A. Hawiger J, et a . Eminpen .us hiorreihesia of
pun ..lo and ihrombosmne and platelet (unction during chronic ad-
mn r,
on of aspirin In man, J Clin Invest 1987 71,676-W
I',v,mi C . .S•m
rin for the prevention of coronary Thrombosis: current
(act, and penpttllres. For Heap 1 10810
.7:$41 .
29. Benigni C E regorini G. Fmsca T . et .1 . Effect ' I., d se aspirin In her oI
and marnrn,, etnarallon of thromboxane by platelets in a omen :o elk fir
pregmracr-indater hppencnsinn . N EndJ I Med 1989 :321357-62 .
I11. Ilerglued L . 011,,l in L . Persistent inhibition of plamelei (unction during
lungaerm boatmen) with 75 me ocewls,lioric acid IASAI daily in men
xith amlahle oxon ;n, artery dtseuse The Heart 1 1991 :11 :428-3).
V . PrichanJ i'J . K'uahiogman GK . Walt RP, Donoshmeod Ti Haakey Cl.
Human gastric nucasai bleeding induced by 1000 dose aspirin, hot not
, ;nfr n . Br Skd 1 1989:'_911:491-6 .
